Form 4: Aytu BioPharma CFO Ryan Selhorn Acquires 14,000 Shares of Restricted Stock

Aytu BioPharma's Chief Financial Officer, Ryan Selhorn, acquired 14,000 shares of restricted stock on November 11, 2024.

Summary

• Ryan J. Selhorn, the Chief Financial Officer of Aytu BioPharma, Inc., acquired 14,000 shares of restricted stock on November 11, 2024.
• The shares were acquired at a price of $0.
• These shares vest over time, with one-third vesting on November 11, 2025, and the remaining shares vesting quarterly through November 11, 2027.
• Following this transaction, Mr. Selhorn directly owns 15,895 common shares.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock grants to a company executive, which is generally viewed as a neutral to slightly positive event, indicating alignment of interests.

Positives

• The acquisition of restricted stock by the CFO could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who acquire or dispose of company stock. It provides transparency into the transactions of key personnel.

Comparison to Industry Standards

• The vesting schedule of the restricted stock is fairly standard, with a portion vesting after one year and the remainder vesting over a subsequent period.
• Many companies use restricted stock as a form of compensation and incentive for executives.

Stakeholder Impact

• The acquisition of restricted stock by the CFO could be viewed positively by shareholders as it aligns management's interests with the company's performance.

Key Dates

Keywords

Aytu BioPharma, Ryan Selhorn, restricted stock, insider trading, equity, vesting